

HSBC Global Funds ICAV (the "ICAV") 3 Dublin Landings North Wall Quay Dublin 1 Ireland

24 July 2023

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to the action you should take you should seek advice from your investment consultant, tax adviser and/or legal adviser as appropriate.

Dear Shareholder,

The purpose of this letter is to notify you of certain changes relating to the HSBC Global Funds ICAV – Global Sukuk Index Fund (the **"Fund"**), a sub-fund of the ICAV.

1. Addition of exchange-traded share classes and change of name

Background

As set out in the notices dated 6 March 2023 and 18 April 2023, a number of exchange-traded share classes in certain sub-funds of the ICAV (**"ETF Shares"**) were established. It is now proposed to also establish ETF Shares in the Fund which means that the Fund must be re-named to include a reference to UCITS ETFs in accordance with the requirements of the Central Bank.

In order to reflect the establishment of ETF Shares in the Fund, it is proposed to change the name of the Fund as follows:

Existing Name	Proposed New Name
HSBC Global Funds ICAV – Global Sukuk Index	HSBC Global Funds ICAV – Global Sukuk UCITS
Fund	ETF

The proposed changes do not change the investment objective and policy of the Fund and do not affect how the Fund is managed.

2. Change to amount that may be invested in collective investment schemes

The limit on investment in Shariah-compliant collective investment schemes that the Fund can make will be reduced from 20% to 10% of its net assets. A prohibition on investing in other sub-funds of the ICAV will also be included in the investment policy for this Fund. The above restrictions are required by certain investors and are expected to expand the distribution potential of the Fund. The restrictions will not result in any alteration to the risk profile of the Fund or asset type held by the Fund.

Registered in Ireland as an open-ended variable capital Irish collective asset-management vehicle and an umbrella fund with segregated liability between sub-funds. Registration Number C173463. Registered Office as above. Directors: Peter Blessing, Eimear Cowhey, Feargal Dempsey, Anthony Jeffs (British), Simon Fryatt (British), Carmen Gonzalez-Calatayud (Spanish)

Effective Date

Subject to the approval of the Central Bank, it is proposed that the above changes will take effect on or around the 18 August 2023 which is the date that the Supplement which includes details of the Fund will be noted by the Central Bank.

You do not need to take any action on receipt of this letter. Should you have any questions or concerns in relation to the above, please contact etfandindexingsales@hsbc.com, the client service team within HSBC Investment Funds (Luxembourg) S.A. ("HIFL") our appointed Management Company in Luxembourg, or the Administrator, HSBC Securities Services (Ireland) DAC.

Additional information, including the Key Investor Information Documents, PRIIPs KIDs, Prospectus, Supplements and most recent financial statements are available by choosing your local website at www.global.assetmanagement.hsbc.com or from the registered office.

Yours sincerely,

For and on behalf of the Board of HSBC Global Funds ICAV

If you have sold or transferred all of your shares in the ICAV, please pass this letter at once to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee as soon as possible.

Unless otherwise defined herein, all capitalised terms used herein shall bear the same meaning as capitalised terms used in the Prospectus, as may be amended from time to time. A copy of the Prospectus is available upon request during normal business hours from the ICAV or from the local representative of the ICAV in any jurisdiction in which the ICAV is registered for public distribution.

The Directors of the ICAV accept responsibility for the accuracy of the information contained in this document. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.

Please note that the Central Bank has not reviewed this letter.